Onesource Specialty Pharma Key Ratios

NSE: ONESOURCE | BSE: 544292

₹1,532.20

up-down-arrow14.70 (0.97%)

As on 28-Aug-2026IST

Market cap

info icon

₹17,579 Cr

Revenue (TTM)

info icon

₹1,543 Cr

P/E Ratio

info icon

--

P/B Ratio

info icon

3

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 4.86 37.20 4.29 124.22 --
EBIT 156.79 149.51 -74.22 74.65 --
Net Profit 492.07 46,957.91 -136.48 22.25 --
EPS 443.63 13,477.30 43.80 25.56 --
Book Value -- -- 430.29 15.42 --
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-25Mar-24
EBIT-Margin info -222.43--3.6313.14-95.70
Net Margin info -404.21---3.12-1.18-207.61
Return on equity info -36.53---0.61-0.55-62.66
Return on Capital info -12.75----2.61-21.41
Return on Assets info -13.70---0.62-0.39-22.05
Debt to Equity (x) info ----0.100.131.45
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
--
2.61
-21.41
-19.43
-2.47
Peer Median
--
14.72
18.85
11.60
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-0.61

Lower than Peers by 11.47

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
-0.61
-0.55
-62.66
-46.39
-9.86
Peer Median
10.86
11.67
14.92
11.46
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-0.62

Lower than Peers by 7.36

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
-0.62
-0.39
-22.05
-18.68
-4.09
Peer Median
6.74
7.86
9.06
6.44
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

3.63

Lower than Peers by 9.06

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
3.63
13.14
-95.70
-584.72
-44.53
Peer Median
12.69
15.03
14.71
12.37
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-3.12

Lower than Peers by 11.98

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
-3.12
-1.18
-207.61
-1,003.83
-75.69
Peer Median
8.86
9.33
8.49
10.02
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
--
17.76
-168.34
-903.98
-36.45
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

4.29

Lower than Peers by 3.85

Year on year growth in net sales

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
4.29
740.43
344.07
-69.80
--
Peer Median
8.14
10.27
11.85
9.08
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-74.22

Lower than Peers by 91.46

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
-74.22
215.42
27.32
-296.56
--
Peer Median
17.24
24.15
28.00
-3.12
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-136.48

Lower than Peers by 153.33

Year on year growth in profit after tax

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
-136.48
95.27
12.02
-316.48
--
Peer Median
16.85
30.29
36.51
-0.85
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

43.80

Higher than Peers by 33.20

Year on year growth in earnings per share

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
43.80
98.39
51.09
-161.96
--
Peer Median
10.60
24.50
--
-6.82
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
--
1,413.25
-50.25
-23.01
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

0.10

Higher than Peers by 0.05

Total debt / Net worth

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
0.10
0.13
1.45
1.07
1.14
Peer Median
0.04
0.23
0.20
0.15
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
--
0.07
0.02
0.25
0.18
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

0.99

Lower than Peers by 0.73

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
0.99
0.98
0.28
0.26
0.63
Peer Median
1.72
1.79
1.96
2.08
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

0.68

Lower than Peers by 0.49

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
0.68
0.83
0.26
0.11
0.29
Peer Median
1.17
1.47
1.44
1.58
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

0.46

Lower than Peers by 7.40

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
0.46
0.60
-3.09
-7.74
-1.15
Peer Median
7.86
9.42
8.58
15.41
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

44.72

Higher than Peers by 18.94

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
44.72
28.83
32.13
9.87
18.45
Peer Median
25.79
25.82
26.12
22.96
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.20

Lower than Peers by 0.47

Sales / Average Total Assets

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
0.20
0.33
0.10
0.02
0.05
Peer Median
0.67
0.75
0.77
0.65
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
--
59.60
62.70
129.47
67.33
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
--
21.38
153.27
1,926.33
784.45
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
--
107.62
455.14
1,407.02
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
--
-26.64
-239.17
648.78
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

-487.20

Lower than Peers by 527.10

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
-487.20
--
--
--
--
Peer Median
39.90
39.70
33.48
37.74
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

3.00

Lower than Peers by 1.23

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
3.00
3.41
--
--
--
Peer Median
4.23
3.72
4.21
3.22
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
--
--
--
--
--
Peer Median
0.10
0.16
0.21
0.57
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

53.19

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
53.19
42.30
-6.02
-4.82
-2,930.49
Peer Median
--
30.23
29.90
28.81
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

17,579

Higher than Peers by 9,967

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Onesource Specialty Pharma
17,579
20,003
--
--
--
Peer Median
7,613
4,851
2,099
15,272
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...